• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 05, 2023 at 10:12: AM
via Novartis AG (NOVN.S) said last week it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.

article source
 

<



Similar threads

cafead
Novartis CEO&#039;s 2023 pay rises 21% as Roche&#039;s helmsman nets $11M in his first year
Replies
0
Views
152
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Replies
0
Views
469
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Roche, Novartis CEOs pull down $12M-plus each in 2021 pay
Replies
0
Views
207
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty
Replies
0
Views
152
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novartis CEO&#039;s 2020 pay drops to $11.6M, no thanks to COVID-19&#039;s drag on sales
Replies
0
Views
208
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote